{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:26:32Z","timestamp":1790007992964,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40265-018-0969-4","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T03:47:52Z","timestamp":1537328872000},"page":"1481-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Elotuzumab: A Review in Relapsed and\/or Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"78","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"969_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","volume":"9","author":"L Naymagon","year":"2016","unstructured":"Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.","journal-title":"J Hematol Oncol"},{"key":"969_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2015.223","volume":"30","author":"S Lonial","year":"2016","unstructured":"Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30:526\u201335.","journal-title":"Leukemia"},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329\u201337.","journal-title":"Blood"},{"issue":"9","key":"969_CR4","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775\u201385.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"969_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"key":"969_CR6","unstructured":"Bristol-Myers Squibb Pharma EEIG. Empliciti: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/ . Accessed 9 Aug 2018."},{"key":"969_CR7","unstructured":"Bristol-Myers Squibb Company. Empliciti\u2122 (elotuzumab) for injection, for intravenous use: US prescribing information. 2017. http:\/\/packageinserts.bms.com\/ . Accessed 9 Aug 2018."},{"key":"969_CR8","unstructured":"Bristol-Myers Squibb. Humanized anti-human SLAMF 7 monoclonal antibody. Empliciti\u00ae for IV infusion: Japanese prescribing information. 2016. http:\/\/www.pmda.go.jp\/ . Accessed 9 Aug 2018."},{"issue":"12","key":"969_CR9","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"SM Collins","year":"2013","unstructured":"Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"969_CR10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","volume":"17","author":"AT Kurdi","year":"2018","unstructured":"Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"969_CR11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood.V110.11.2517.2517","volume":"110","author":"AG Rice","year":"2007","unstructured":"Rice AG, Dillon MBC, Van Abbema AM, et al. HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumour activity in pre-clinical models of myeloma. Blood. 2007;110(11):2517.","journal-title":"Blood"},{"issue":"1","key":"969_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","volume":"64","author":"B Balasa","year":"2015","unstructured":"Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015;64(1):61\u201373.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"969_CR13","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","volume":"8","author":"F Rhee Van","year":"2009","unstructured":"Van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"969_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896\u2013905.","journal-title":"Br J Haematol"},{"issue":"12","key":"969_CR15","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","volume":"2","author":"PG Richardson","year":"2015","unstructured":"Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516\u201327.","journal-title":"Lancet Haematol"},{"issue":"3","key":"969_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10928-016-9469-x","volume":"43","author":"L Gibiansky","year":"2016","unstructured":"Gibiansky L, Passey C, Roy A, et al. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed\/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243\u201357.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"969_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1208\/s12248-016-0033-9","volume":"19","author":"C Passey","year":"2017","unstructured":"Passey C, Mora J, Dodge R, et al. An integrated assessment of the effects of immunogenicity on the pharmacokinetics, safety, and efficacy of elotuzumab. AAPS J. 2017;19(2):557\u201367.","journal-title":"AAPS J"},{"key":"969_CR18","unstructured":"European Medicines Agency. Empliciti: CHMP assessment report. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 9 Aug 2018."},{"issue":"3","key":"969_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","volume":"16","author":"J Berdeja","year":"2016","unstructured":"Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129\u201338.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"969_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31680","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018. https:\/\/doi.org\/10.1002\/cncr.31680 .","journal-title":"Cancer."},{"issue":"3","key":"969_CR21","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1038\/bcj.2017.18","volume":"7","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Sunami K, Ohashi K, et al. Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood Cancer J. 2017;7(3):e540.","journal-title":"Blood Cancer J"},{"key":"969_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3469-4","author":"D Cella","year":"2018","unstructured":"Cella D, McKendrick J, Kudlac A, et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Ann Hematol. 2018. https:\/\/doi.org\/10.1007\/s00277-018-3469-4 .","journal-title":"Ann Hematol."},{"key":"969_CR23","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma (version 4.2018). 2018. http:\/\/www.nccn.org\/ . Accessed 9 Aug 2018."},{"issue":"Suppl 6","key":"969_CR24","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdx367.033","volume":"24","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;24(Suppl 6):vi133\u20137.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"969_CR25","first-page":"5599","volume":"130","author":"S Ailawadhi","year":"2017","unstructured":"Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma (RRMM) [abstract no. 5599]. Blood. 2017;130(Suppl 1):5599.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0969-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T05:40:06Z","timestamp":1604986806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0969-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":25,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0969-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"19 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yvette Lamb is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}